Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Telecobalt therapy for malignant lung tumours.

N Ghilezan, N Milea, S Tamburlini

    Acta Radiologica: Therapy, Physics, Biology
    |October 1, 1976
    PubMed
    Summary

    Telecobalt therapy for malignant lung tumors showed low 3- and 5-year survival rates of 9.7% and 5.4%. Treatment outcomes were influenced by tumor microscopy, clinical stage, and irradiation techniques.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2008
    Same author

    Quality of life and treatment related toxicity in 335 patients with locally advanced cervical carcinoma treated by two chemoradiation regimens.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2007
    Same author

    Clinical results of medium dose rate brachytherapy combined with external beam radiotherapy in the treatment of advanced cervical carcinoma.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2007
    Same author

    First-line chemotherapy with topotecan and etoposide in advanced small cell lung cancer. A phase II study.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2007
    Same author

    Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2007
    Same author

    Paclitaxel and carboplatin in relapsed or metastatic nasopharyngeal carcinoma: a multicenter phase II study.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2007

    Area of Science:

    • Oncology
    • Radiotherapy

    Background:

    • Malignant lung tumors represent a significant health challenge.
    • Historical treatment modalities like telecobalt therapy have been employed.

    Purpose of the Study:

    • To report the outcomes of telecobalt therapy for lung cancer.
    • To analyze survival rates and prognostic factors in treated patients.

    Main Methods:

    • Retrospective analysis of 194 patients with malignant lung tumors.
    • Treatment administered between 1967 and 1971 using telecobalt therapy.
    • Evaluation of survival data and influencing factors.

    Main Results:

    • 3-year survival rate: 9.7%
    • 5-year survival rate: 5.4%
    • Average survival: 15 months.

    Conclusions:

    • Telecobalt therapy yielded limited long-term survival for lung cancer patients.
    • Microscopy, clinical staging, and irradiation techniques significantly impacted patient prognosis.
    • Identification of distinct prognostic groups is possible based on these factors.

    Related Experiment Videos